Advertisement

New Galenic Formulations of Melatonin

  • Pilar García-García
  • Francisco López-Muñoz
  • Cecilio Álamo
Chapter

Abstract

Melatonin is a neurohormone that plays an important role in maintaining the body’s internal biological clock (the sleep-wake and thermoregulatory system). Its main role is in relation to circadian rhythms and it also acts as an antioxidant. The pharmacokinetic characteristics of melatonin include a short half-life and extensive metabolism, leading to a short action when exogenous formulations are administered. For this reason, different formulations have been developed to increase and prolong the actions of melatonin.

Keywords

Sleep Quality Pittsburgh Sleep Quality Index Galenic Formulation Primary Insomnia Melatonin Administration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Acuña-Castroviejo D, Escames G, Venegas C, et al. Extrapineal melatonin: sources, regulation and potential functions. Cell Mol Life Sci. 2014;16:2997–3025.CrossRefGoogle Scholar
  2. 2.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Publishing; 2013.CrossRefGoogle Scholar
  3. 3.
    Arendt J, Bojkowski C, Franey C, et al. Immunoassay of 6-hydroxymelatonin sulfate in human plasma and urine: abolition of the urinary 24-h rhythm with atenolol. J Clin Endocrinol Metab. 1985;60:1166–73.CrossRefPubMedGoogle Scholar
  4. 4.
    Bartoli A, De Gregori S, Molinaro M, et al. Bioavalability of a new oral spray melatonin emulsion compared with standard oral formulation in healthy volunteers. J Bioequiv Availab. 2012;4:7.Google Scholar
  5. 5.
    Bechgaard E, Lindhardt K, Martinsen L. Intranasal absorption of melatonin in vivo bioavailability study. Int J Pharm. 1999;182:1–5.CrossRefPubMedGoogle Scholar
  6. 6.
    Benes L, Claustrat B, Horrière F, et al. Transmucosal, oral controlled-release, and transdermal drug administration in human subjects: a crossover study with melatonin. J Pharm Sci. 1997;86:115–9.CrossRefGoogle Scholar
  7. 7.
    Benloucif S, Burgess HJ, Klerman EB, et al. Measuring melatonin in human. J Clin Sleep Med. 2008;4:66–9.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Buysse DJ, Dorsey CM. Current and experimental therapeutics of insomnia. In: Davis KL, Charney D, Coyle JT, Neroff C, editors. Neuropsychopharmacology: the fifth generation of progress. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 1931–43.Google Scholar
  9. 9.
    Cajochen C, Drauchi K, Wirz-Justice A. Role of melatonin in the regulation of human circadian rhythms and sleep. J Neuroendocrinol. 2003;15:432–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Cavallo A, Hassan M. Stability of melatonin in aqueous solution. J Pineal Res. 1995;18:90–2.CrossRefPubMedGoogle Scholar
  11. 11.
    Chen JM, Mao SR, Bi DZ. Studies on melatonin gelatin microspheres for intranasal administration. Yao Xue Xue Bao. 2000;35:786–9.PubMedGoogle Scholar
  12. 12.
    Czeisler CA, Duffy JF, Shanahan TL, et al. Stability, precision, and near-24-hour period of the human circadian pacemaker. Science. 1999;284(5423):2177–81.CrossRefPubMedGoogle Scholar
  13. 13.
    Dawson D, Rogers NL, van den Heuvel CJ, et al. Effect of sustained nocturnal transbuccal melatonin administration on sleep and temperature in elderly insomniacs. J Biol Rhythms. 1998;13:532–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Daya S, Walker RB, Glass BD, Anoopkumar-Dukie S. The effect of variations in pH and temperature on stability of melatonin in aqueous solution. J Pineal Res. 2001;31:155–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Dhanan PS, Mis R. The benzodiazepine problem in primary care: the seriousness and solutions. Qual Prim Care. 2005;13:221–4.Google Scholar
  16. 16.
    Di W, Kadva A, Johston A, Silman R. Variable bioavailability of oral melatonin. NEJM. 1997;3:1928–9.Google Scholar
  17. 17.
    Dubey V, Mishra D, Jain NK. Melatonin loaded ethanolic liposomes: physicochemical characterization and enhanced transdermal delivery. Eur J Pharm Biopharm. 2007;67:398–405.CrossRefPubMedGoogle Scholar
  18. 18.
    EMA (European Medicines Agency). Circadin: European medicines agency public assessment reports for circadin. Available from: http://www.emea.europa.eu/humandocs/Humans/EPAR/circadin/circadin.htm. Accessed 2012.
  19. 19.
    EMA (European Medicines Agency). Circadin: product information (SPC). http://www.ema.europa.eu/docs/En_GB/document_library/EPAR_Product_Information/human/000695/WC500026811.pdf. Accessed 2012.
  20. 20.
    Fischer TW, Elsner P. The antioxidative potential of melatonin in the skin. Curr Probl Dermatol 2001; 29:165–74.Google Scholar
  21. 21.
    Fischer TV, Greif C, Fluhr JW, et al. Percutaneous penetration of topically applied melatonin in a cream and an alcoholic solution. Skin Pharmacol Physiol. 2004;14:190–4.CrossRefGoogle Scholar
  22. 22.
    Fischer TW, Sweatman TW, Semak I, et al. Constitutive and UV-induced metabolism of melatonin in keratinocytes and cell-free systems. FASEB J 2006;20:1564–6.Google Scholar
  23. 23.
    George A, Poeggeler B, Huether G. Melatonin measurements in tissues. Different recovery of endogenously contained and exogenously added melatonin. Adv Exp Med Biol. 1996;398:691–6.CrossRefPubMedGoogle Scholar
  24. 24.
    Gooneratne NS, Edwards AYZ, Zhou C, et al. Melatonin pharmacokinetics following two different oral surge-sustained release doses in older adults. J Pineal Res. 2012;52:437–45.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Hafner A, Lovrić J, Voinovich D, Filipović-Grcić J. Melatonin-loaded lecithin/chitosan nanoparticles: physicochemical. Characterisation and permeability through caco-2 cell WEI-LI monolayers. Int J Pharm. 2009;381:205–13.CrossRefPubMedGoogle Scholar
  26. 26.
    Ham H, Kujawa J, Augsburger L. Comparison of melatonin products against USP’s nutritional supplements standards and other criteria. J Am Pharm Assoc (Wash). 1999;39:27–31.CrossRefGoogle Scholar
  27. 27.
    Hattori A, Migitaka H, Iigo M, et al. Identification of melatonin in plants and its effects on plasma melatonin levels and binding to melatonin receptors in vertebrates. Biochem Mol Biol Int. 1995;35:627–34.PubMedGoogle Scholar
  28. 28.
    Johns J, Chenboonthai C, Pratheepawanit J, et al. An intravenous injections of melatonin: formulations, stability, pharmacokinetics and pharmacodynamics. JAASP. 2012;1:32–43.Google Scholar
  29. 29.
    Johns NP, Johns J, Porasuphatana S, et al. Dietary intake of melatonin from tropical fruit altered urinary excretion of 6-sulfatoxymelatonin in healthy volunteers. J Agric Food Chem. 2013;30:913–9.CrossRefGoogle Scholar
  30. 30.
    Kanikkannan N, Andega S, Burton S, et al. Formulation and in vitro evaluation of transdermal patches of melatonin. Drug Dev Ind Pharm. 2004;30:205–12.CrossRefPubMedGoogle Scholar
  31. 31.
    Kennaway DJ, Lushington K, Dawson D, et al. Urinary 6-sulfatoxymelatonin excretion and aging: new results and a critical review of the literature. J Pineal Res. 1999;27:210–20.CrossRefPubMedGoogle Scholar
  32. 32.
    Kikwai L, Kanikkannan N, Babu RJ, Singh M. Effect of vehicles on the transdermal delivery of melatonin across porcine skin in vitro. J Control Release. 2002;83:307–11.CrossRefPubMedGoogle Scholar
  33. 33.
    Kunz D, Bineau S, Maman K, et al. Benzodiazepine discontinuation with prolonged-release melatonin: hints from a German longitudinal prescription database. Expert Opin Pharmacother. 2012;13:9–16.CrossRefPubMedGoogle Scholar
  34. 34.
    Leger D, Guilleminault C, Bader G, et al. Medical and socio-professional impact of insomnia. Sleep. 2002;25:625–9.PubMedGoogle Scholar
  35. 35.
    Leger D, Laudon M, Zisapel N. Nocturnal 6-sulfatoxymelatonin excretion in insomnia and its relation to the response to melatonin replacement therapy. Am J Med. 2004;116:91–5.CrossRefPubMedGoogle Scholar
  36. 36.
    Lemoine P, Nir T, Laudon M, Zisapel N. Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res. 2007;16:372–80.CrossRefPubMedGoogle Scholar
  37. 37.
    Lemoine P, Zisapel N. Prolonged-release formulation of melatonin (Circadin) for the treatment of insomnia. Expert Opin Pharmacother. 2012;13:895–905.CrossRefPubMedGoogle Scholar
  38. 38.
    Lewy AJ, Ahmed S, Sack RL. Phase shifting the human circadian clock using melatonin. Behav Brain Res. 1996;73:131–4.CrossRefPubMedGoogle Scholar
  39. 39.
    Luthringer R, Muzet M, Zisapel N, Staner L. The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia. Int Clin Psychopharmacol. 2009;24:239–49.CrossRefPubMedGoogle Scholar
  40. 40.
    Mallo C, Zaidan R, Galy G, et al. Pharmacokinetics of melatonin in man after intravenous infusion and bolus injection. Eur J Clin Pharmacol. 1990;38:297–301.CrossRefPubMedGoogle Scholar
  41. 41.
    Mao S, Chen J, Wei Z, Liu H, Bi D. Intranasal administration of melatonin starch microspheres. Int J Pharm. 2004;272:37–43.CrossRefPubMedGoogle Scholar
  42. 42.
    Mercolini L, Mandrioli R, Raggi MA. Content of melatonin and other antioxidants in grape-related foodstuffs: measurement using a MEPS-HPLC-F method. J Pineal Res. 2012;53:21–8.CrossRefPubMedGoogle Scholar
  43. 43.
    Novak M, Mucsi I, Shapiro CM, et al. Increased utilization of health services by insomniacs – an epidemiological perspective. J Psychosom Res. 2004;56:527–36.CrossRefPubMedGoogle Scholar
  44. 44.
    Oh HJ, Oh YK, Kim CK. Effects if vehicles and enhancers on transdermal delivery of melatonin. In J Pharm. 2001;212:63–71.Google Scholar
  45. 45.
    Proietti S, Carlomagno G, Dinicola S, Bizzarri M. Soft gel capsules improve melatonin’s bioavailability in humans. Expert Opin Drug Metab Toxicol. 2014;10(9):1–6.CrossRefGoogle Scholar
  46. 46.
    Roth T. Insomnia: definition, prevalence, etiology, and consequences. J Clin Sleep Med. 2007;3:S7–10.PubMedPubMedCentralGoogle Scholar
  47. 47.
    Saracino MA, Mercolini L, Musenga A, et al. Comparison of analytical methods for the quality control of a new formulation containing soy extract and melatonin. J Sep Sci. 2008;31:1851–9.CrossRefPubMedGoogle Scholar
  48. 48.
    Shah T, Tse A, Gill H, et al. Administration of melatonin mixed with soft food and liquids for children with neurodevelopmental difficulties. Dev Med Child Neurol. 2008;50:845–9.CrossRefPubMedGoogle Scholar
  49. 49.
    Sherk Y, Smith BA, Miller BD. Liquid melatonin via gastrostomy as an alternative hypnotic in a child with pervasive developmental disorder. J Child Adolesc Psychopharmacol. 2011;21:291–3.CrossRefPubMedGoogle Scholar
  50. 50.
    Shirakawa S, Tsuchiya S, Tsutsumi Y, et al. Time course of saliva and serum melatonin levels after ingestion of melatonin. Psychiatry Clin Neurosci. 1998;52:266–7.CrossRefPubMedGoogle Scholar
  51. 51.
    Siriwardena AN, Qureshi MZ, Dyas JV, et al. Magic bullets for insomnia? Patients’ use and experiences of newer (Z drugs) versus older (benzodiazepine) hypnotics for sleep problems in primary care. Br J Gen Pract. 2008;58:417–22.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Suhner A, Werner I, Wilde A, Schlagenhauf P. Over-the-counter melatonin – quality or quackery? Pharmazie. 1999;54:863–4.PubMedGoogle Scholar
  53. 53.
    Tan DX, Manchester LC, Hardeland R, et al. Melatonin: a hormone, a tissue factor, an autocoid, and an antioxidant vitamin. J Pineal Res. 2003;34:75–8.CrossRefPubMedGoogle Scholar
  54. 54.
    Taylor DJ, Mallory LJ, Lichstein KL, et al. Comorbidity of chronic insomnia with medical problems. Sleep. 2007;30:213–8.PubMedGoogle Scholar
  55. 55.
    van Woensel M, Wauthoz N, Rosière R, et al. Formulations for intranasal delivery of pharmacological agents to combat brain disease: a new opportunity to tackle GBM? Cancers. 2013;5:1020–48.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Vural E, van Munster B, de Rooij S. Optimal dosages for melatonin supplementation therapy in older adults: a systematic review of current literature. Drugs Aging. 2014;31:441–51.CrossRefPubMedGoogle Scholar
  57. 57.
    Wade AG, Ford I, Crawford G, et al. Efficacy of prolonged release melatonin in insomnia patients aged 55–80 years: quality of sleep and next-day alertness outcomes.Curr Med Res Opin. 2007; 23:10.Google Scholar
  58. 58.
    Wade AG, Ford I, Crawford G, et al. Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety. BMC Med. 2010;16:51.CrossRefGoogle Scholar
  59. 59.
    Waldhauser F, Waldhauser M, Lieberman HR, et al. Bioavailability of oral melatonin in humans. Neuroendocrinology. 1984;39:307–13.CrossRefPubMedGoogle Scholar
  60. 60.
    Walsh JK, Coulouvrat C, Hajak G, et al. Nighttime insomnia symptoms and perceived health in the America Insomnia Survey (AIS) running heading: nighttime insomnia symptoms in the AIS. Sleep. 2011;34:997–1011.PubMedPubMedCentralGoogle Scholar
  61. 61.
    Wilson SJ, Nutt DJ, Alford C, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol. 2010;24:1577–601.CrossRefPubMedGoogle Scholar
  62. 62.
    Zisapel N. Development of a melatonin-based formulation for the treatment of insomnia in the elderly. Drug Dev Res. 2000;50:226–34.CrossRefGoogle Scholar
  63. 63.
    Zisapel N. In: The Role of Melatonin in Sleep Regulation. Neuroendocrine Correlates of Sleep/Wakefulness. 2005. pp 295–309.Google Scholar
  64. 64.
    Zisapel N. Controlled release melatonin (Circadin) in the treatment of insomnia in older patients: efficacy and safety in patients with history of use and non-use of hypnotic drugs. Harefuah. 2009;148:337–41.PubMedGoogle Scholar

Copyright information

© Springer India 2016

Authors and Affiliations

  • Pilar García-García
    • 1
  • Francisco López-Muñoz
    • 2
    • 3
    • 4
  • Cecilio Álamo
    • 1
  1. 1.Department of Biomedical Sciences (Pharmacology Area), Faculty of Medicine and Health SciencesUniversity of AlcaláMadridSpain
  2. 2.Faculty of Health SciencesCamilo José Cela UniversityMadridSpain
  3. 3.Neuropsychopharmacology UnitHospital 12 de Octubre Research Institute (i+12)MadridSpain
  4. 4.Portucalense Institute of Neuropsychology and Cognitive and Behavioural NeurosciencesPortucalense UniversityPortoPortugal

Personalised recommendations